Noxopharm (ASX:NOX) has announced the addition of three US sites for its CEP-2 sarcoma study - Washington University in St Louis and two Mayo Clinic sites in Florida and Minnesota.
The company said the participation of these new sites reinforces its ability to attract leading medical researchers.
The three new sites are in addition to the City of Hope Cancer Center which is currently treating patients with Veyonda and doxorubicin for metastatic soft tissue sarcoma.
Noxopharm CEO Dr Gisela Mautner said, “We are delighted to have such prestigious institutions participating in the CEP-2 trial investigating treatments for soft tissue sarcoma, a challenging cancer with few treatment options. It is our hope that we will identify an effective treatment to improve outcomes and quality of life for sarcoma patients worldwide."